Efficacy and prognosis of different interventional psychiatric treatments for patients with severe depression
DOI:
https://doi.org/10.62051/ygt4nv07Keywords:
Major depressive disorder; Interventional psychiatry; therapy.Abstract
This review examines the efficacy and prognosis of various interventional psychiatric treatments for patients with severe depression. Major depressive disorder (MDD), characterized by persistent low mood and loss of interest, is a significant global health issue, particularly prevalent among younger populations and exacerbated by the COVID-19 pandemic. Despite the availability of multiple pharmacological, psychotherapeutic, and specialized physical treatments for MDD, the overall prognosis remains poor. Consequently, physical treatments such as electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), and deep brain stimulation (DBS) have emerged as interventional psychiatric therapies for recurrent and treatment-resistant depression. Studies indicate that ECT is the preferred treatment for severe and refractory depression due to its rapid onset of action; rTMS is more suitable for long-term management of mild to moderate refractory depression because of its non-invasive nature; and tDCS, with its portability and safety, is often used as an adjunct to pharmacotherapy or psychotherapy. These interventional treatments have complementary value in treating treatment-resistant depression and are expected to improve efficacy and expand clinical applications in the future with the optimization of nutriregulation techniques and the advancement of interdisciplinary research.
Downloads
References
[1] COVID-19 Mental Disorders Collaborators. (2021). Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. The Lancet, 398 (10312), 1700 – 1712.
[2] Verduijn, J., Verhoeven, J. E., Milaneschi, Y., Schoevers, R. A., van Hemert, A. M., Beekman, A. T. F., & Penninx, B. W. J. H. (2017). Reconsidering the prognosis of major depressive disorder across diagnostic boundaries: Full recovery is the exception rather than the rule. BMC Medicine, 15 (1), 215. DOI: https://doi.org/10.1186/s12916-017-0972-8
[3] Sackeim, H. A., Prudic, J., Devanand, D. P., et al. (2020). The benefits and costs of changing treatment technique in electroconvulsive therapy due to insufficient improvement of a major depressive episode. Brain Stimulation, 13, 1284 – 1295. DOI: https://doi.org/10.1016/j.brs.2020.06.016
[4] Bahji, A., Hawken, E. R., Sepehry, A. A., Cabrera, C. A., & Vazquez, G. (2019). ECT beyond unipolar major depression: Systematic review and meta-analysis of electroconvulsive therapy in bipolar depression. Acta Psychiatrica Scandinavica, 139 (3), 214 – 226. DOI: https://doi.org/10.1111/acps.12994
[5] Fink, M., Kellner, C. H., & McCall, W. V. (2014). The role of ECT in suicide prevention. Journal of ECT, 30, 5 – 9. DOI: https://doi.org/10.1097/YCT.0b013e3182a6ad0d
[6] Bikson, M., Ghobadi-Azbari, P., & Woods, A. J. (2023). Personalized tDCS for cognitive rehabilitation in traumatic brain injury: A machine learning approach. Brain Stimulation, 16 (3), 789 – 798.
[7] Barker, A. T., Jalinous, R., & Freeston, I. L. (1985). Non-invasive magnetic stimulation of human motor cortex. The Lancet, 1 (8437), 1106 – 1107. DOI: https://doi.org/10.1016/S0140-6736(85)92413-4
[8] Huang, C.-C., Su, T.-P., & Shan, I.-K. (2004). A case report of repetitive transcranial magnetic stimulation-induced mania. Bipolar Disorders, 6, 444 – 445. DOI: https://doi.org/10.1111/j.1399-5618.2004.00145.x
[9] Hassanzadeh, E., Moradi, G., Arasteh, M., & Moradi, Y. (2024). The effect of repetitive transcranial magnetic stimulation on the Hamilton Depression Rating Scale-17 criterion in patients with major depressive disorder without psychotic features: A systematic review and meta-analysis of intervention studies. BMC Psychology, 12 (1), 480. DOI: https://doi.org/10.1186/s40359-024-01981-6
[10] Voidness’s, D., & Blumberger, D. M. (2023). Transcranial direct current stimulation as a treatment for major depressive disorder. The Lancet, 402 (10401), 506 – 507. DOI: https://doi.org/10.1016/S0140-6736(23)00822-X
[11] LeLacheur, J. P., Antal, A., Ayache, S. S., Benninger, D. H., Brunelin, J., Cogiamanian, F., Cotelli, M., De Ridder, D., Ferrucci, R., Langguth, B., Marangolo, P., Mylius, V., Nitsche, M. A., Padberg, F., Palm, U., Poulet, E., Priori, A., Rossi, S., Schecklmann, M., Vanneste, S., … Paulus, W. (2017). Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clinical Neurophysiology, 128 (1), 56 – 92. DOI: https://doi.org/10.1016/j.clinph.2016.10.087
[12] Arns, M., et al. (2016). EEG alpha asymmetry as a gender-specific predictor of outcome to acute treatment with different antidepressant medications. Clinical Neurophysiology, 127 (1), 509 – 519. DOI: https://doi.org/10.1016/j.clinph.2015.05.032
[13] Brunoni, A. R., et al. (2015). BDNF blood levels after non-invasive brain stimulation interventions in major depressive disorder: A systematic review and meta-analysis. World Journal of Biological Psychiatry, 16 (2), 114 – 122. DOI: https://doi.org/10.3109/15622975.2014.958101
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Transactions on Materials, Biotechnology and Life Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
